Given that the genetic and pharmacological perturbation of p300 activity both led to a marked reduction in tumor cell proliferation in vitro, we next sought to determine whether p300 inhibition could represent a viable strategy to decrease CDS tumor growth in vivo. The gene discussed is EP300; the disease is neoplasm.